[red] has taken this same mythology learned with cannabis and cannabimimetics and applied it to the medical 

mushroom market including "Psilocybin".  

 

Working with partners [red] has been able to extract from the solid plant matter the medicinal elements intact, increasing the bioavailability of the medicine.  

 

This opens the doors for brands to be able to develop consumer products that are more effective and with more accurate dosing capabilities. We are working with partners on dissolvable oral strips and water soluble based medical applications such as oral liquids, capsules, and effervescent tablets.

​

[red]'s proprietary extraction technology, along with proprietary formulations for several specific disease targets and physician-led therapy protocols that have proven to be effective for several specific disease targets. In parallel with psilocybin moving into the pharmaceutical research realm, [red] will continue to develop its pharmaceutical research infrastructure. 

​

Building upon our experience with sleep disorders & PTSD, we are expanding our research and treatment options to encompass depression, anxiety, and general mental health. This puts [red] in the unique position to provide a full-scope, closed-loop therapy protocol. 

​

A timeline leading towards [red] as being positioned as a leader in this space:

• In 2018, the FDA recognized psilocybin therapies as a “breakthrough” therapy for PTSD and Major Depressive Disorder. (Food and Drug Administration, 2018).

• In 2019, Imperial College of London and John Hopkins open the first psychedelic research centers. MAPS clinics across the nation conduct research on psilocybin therapy. (Forbes.com, 2019).

• In 2020, Health Canada approves psilocybin for select patients with a terminal illness. 2020 Oregon State decriminalizes psilocybin. On November 30, 2020, Oregon state issues a call for participants in the State Guidance Committee. 

• 2021, [red] will submit a provisional patent on drug formulation containing psilocybin and a combination of additional functional mushrooms for the disease targets of PTSD, depression, and general anxiety. 

​

[red]’s initial focus will be on pharmaceutical/nutraceutical R&D for Brands & partners who are entering the Oregon State market with additional markets to follow as legislation allows. 

​

[red] is in the process of applying for a Section 56 exemption in Canada that will allow for Physicians to be able to prescribe [red]’s formulation to veterans and first responders. With this infrastructure in place, [red] will be able to be one of the first companies to come to market in the psilocybin space with both psilocybin products augmented by [red]’s current natural health and cannabimimetic-derived pharma products.

​

[red] has developed its Psilocybin brand CYBINAL, all natural formulations that allow for better bioabsorption and increases accurate dosing.